Major Growth Driver Identified in 2025 Therapeutic BCG Vaccines Market: Fighting Tuberculosis Surging Global Cases Propel Growth In The Therapeutic Bcg Vaccine Market

Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations.

Therapeutic BCG Vaccines Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The therapeutic bcg vaccines market size has grown strongly in recent years. It will grow from $56.47 billion in 2024 to $59.66 billion in 2025 at a compound annual growth rate (CAGR) of 5.7%. The growth in the historic period can be attributed to government initiatives for tb control, immune system modulation, global immunization programs, treatment of bladder cancer, investments in vaccine manufacturing, emergence of drug-resistant tb strains.

Therapeutic BCG Vaccines Market Size Forecast: What's the Projected Valuation by 2029?
The therapeutic bcg vaccines market size is expected to see strong growth in the next few years. It will grow to $77.17 billion in 2029 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period can be attributed to expansion to other indications, increased research on immunotherapy, global efforts against emerging infectious diseases, regulatory support for vaccine development, focus on tuberculosis elimination. Major trends in the forecast period include advancements in vaccine technology, supply chain optimization, market consolidation and partnerships, patient education and awareness, alternative delivery methods, personalized medicine approaches.

View the full report here:
https://www.thebusinessresearchcompany.com/report/therapeutic-bcg-vaccines-global-market-report

What Are the Drivers Transforming the Therapeutic BCG Vaccines Market?
The rising number of tuberculosis (TB) cases worldwide will propel the growth of the therapeutic BCG vaccine market going forward. Tuberculosis (TB) is an infectious illness that can be potentially dangerous and primarily impacts the lungs. People can contract tuberculosis from one another by coughing or sneezing small droplets of bacteria into the air. BCG vaccines are used to stimulate the immune system to fight infection but do not cause TB since the germs are weak. It consistently offers protection against the most dangerous types of TB, such as adolescent TB meningitis. The BCG vaccine protects against tuberculosis which helps to fight against infection, hence the usage of therapeutic BCG vaccines increased. For instance, in February 2024, according to a report published by the UK Health Security Agency, a UK-based government agency, tuberculosis (TB) cases in England increased by 10.7% in 2023, with 4,850 cases reported compared to 4,380 in 2022 . Therefore, the rising number of tuberculosis (TB) cases worldwide is driving the growth of the therapeutic BCG vaccine market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9178&type=smp

What Long-Term Trends Will Define the Future of the Therapeutic BCG Vaccines Market?
Strategic partnerships have emerged as a key trend gaining popularity in the therapeutic BCG vaccine market. Major companies operating in the therapeutic BCG vaccine market are focused on collaborating with other key players to sustain their position in the market. For instance, in May 2024, ImmunityBio, a US-based biotechnology company, partnered with Serum Institute of India, an India-based biotechnology and biopharmaceuticals company, to secure a supply of the Bacillus Calmette-Guerin (BCG) vaccine for all cancer types. The partnership focuses on producing the standard BCG (sBCG) approved for use outside the US and a next-generation recombinant BCG (iBCG) currently undergoing tests. iBCG is intended for use along with ImmunityBio's ANKTIVA (nogapendekin alfa inbakicept-PMLN) for approved and additional future indications, contingent on regulatory approvals.

Which Segments in the Therapeutic BCG Vaccines Market Offer the Most Profit Potential?
The therapeutic bcg vaccines market covered in this report is segmented -

1) By Type: Therapy BCG, Immune BCG
2) By Demographics: Pediatrics, Adults
3) By End Use: Hospitals, Clinics, Other End Users

Subsegments:
1) By Therapy BCG: Intravesical BCG, Injectable BCG
2) By Immune BCG: BCG For Immune Enhancement, BCG For Allergy Treatment

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=9178&type=smp

Which Firms Dominate the Therapeutic BCG Vaccines Market by Market Share and Revenue in 2025?
Major companies operating in the therapeutic bcg vaccines market include Merck & Co Inc., Sanofi Pasteur, Japan BCG Laboratory, China National Biotec Group, Serum Institute of India Pvt. Ltd., InterVax Ltd., GreenSignal Bio Pharma Limited, Statens Serum Institute, AJ Vaccines, Bul Bio-National Center of Infectious and Parasitic Diseases Ltd, Biomed Lublin S.A., Microgen, Taj Pharma Ltd., PT Bio Farma, Torlak Institute of Virology, Bacille Bilie Calmette-Guerin Laboratory, China Biotechnology Co Ltd., Bharat Biotech International Ltd., Biological E. Limited, Shanghai Institute of Biological Products Co. Ltd., Cipla Limited, Instituto Butantan

Which Regions Offer the Highest Growth Potential in the Therapeutic BCG Vaccines Market?
Asia-Pacific was the largest region in the therapeutic BCG vaccines market in 2024. The regions covered in the therapeutic bcg vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=9178

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Learn More About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.